Related Experiment Video
Updated: Aug 2, 2025

An In Vitro Model of a Parallel-Plate Perfusion System to Study Bacterial Adherence to Graft Tissues
Published on: January 7, 2019
Transcatheter Aortic Valve Replacement for Aortic Valve Infective Endocarditis: A Systematic Review and Call for
Milos Brankovic1,2, Ashkan Hashemi1, Julia Ansari3
1Department of Medicine, Rutgers New Jersey Medical School, Newark, NJ, USA.
Insights
Transcatheter aortic valve replacement (TAVR) may be a viable option for select patients with active aortic valve infective endocarditis (AV-IE) and prohibitive surgical risk. This review highlights TAVR
Area of Science:
- Cardiology
- Interventional Cardiology
- Cardiac Surgery
Background:
- Active aortic valve infective endocarditis (AV-IE) poses significant risks, with surgery often declined due to prohibitive surgical risk.
- Transcatheter aortic valve replacement (TAVR) presents a potential alternative for high-risk patients with AV-IE.
- TAVR may serve as a bridge-to-surgery or standalone therapy in carefully selected AV-IE cases.
Purpose of the Study:
- To systematically analyze the existing literature on the application of TAVR in patients with active AV-IE.
- To evaluate the feasibility and outcomes of TAVR in patients with AV-IE who are not surgical candidates.
- To identify the role of TAVR as an adjuvant therapy for AV-IE in specific patient populations.
Main Methods:
- Systematic literature search of PubMed/MEDLINE, Embase, and Cochrane databases (2002-2022).
- Inclusion criteria focused on studies reporting TAVR use in active AV-IE.
- Analysis of six eligible studies involving patients with prohibitive surgical risk and AV-IE.
Main Results:
- Six studies met criteria, all involving male patients (mean age 71 years) with high surgical risk scores (STS 27, EuroSCORE 56).
- All patients presented with severe or moderate aortic regurgitation and cardiogenic shock, often due to prosthetic valve endocarditis.
- No in-hospital mortality or myocardial infarction; one stroke occurred within 30 days. Median event-free time was 9 months, with no deaths or reinfections.
Conclusions:
- TAVR can be considered an adjuvant therapy for selected patients with acute heart failure secondary to AV-IE who have prohibitive surgical risk.
- Current evidence supports TAVR for acute hemodynamic compromise in AV-IE, not for active infection control or septic embolization.
- A prospective registry is crucial to further investigate the outcomes of this off-label TAVR indication.
Abstract:
We aimed to systematically analyze the literature on the use of transcatheter aortic valve replacement (TAVR) to treat active aortic valve infective endocarditis (AV-IE). Surgery is declined in one-third of patients with IE who meet indications because of prohibitive surgical risk. TAVR might be an alternative for selected patients with AV-IE as a bridge-to-surgery or stand-alone therapy. PubMed/MEDLINE, Embase, and Cochrane databases were searched (2002-2022) for studies on TAVR use in active AV-IE. Of 450 identified reports, six met inclusion criteria (all men, mean age 71 ± 12 years, median Society of Thoracic Surgeons (STS) score 27, EuroSCORE 56). All patients were prohibitive surgical risk candidates. Five out of six patients had severe, and one patient had moderate aortic regurgitation on presentation. Five out of six patients had prosthetic valve endocarditis after surgical valve replacement 13 years before (median), and one patient had TAVR a year before hospitalization. All patients had cardiogenic shock as the indication for TAVR. Four patients received balloon-expanding, and two patients received self-expanding TAVR after a median of 19 (IQR 9-25) days from diagnosis of IE. No death or myocardial infarction occurred, but one patient had a stroke within the first 30 days. The median event-free time was 9 (IQR 6-14) months including no death, reinfection, relapse IE, or valve-related rehospitalization. Our review suggests that TAVR can be considered as an adjuvant therapy to medical treatment for selected patients in whom surgery is indicated for treatment of acute heart failure due to aortic valve destruction and incompetence caused by infective endocarditis, but who have a prohibitive surgical risk. Nonetheless, a well-designed prospective registry is urgently needed to investigate the outcomes of TAVR for this off-label indication. No evidence exists for using the TAVR to treat infection-related surgical indications such as uncontrolled infection or control of septic embolization.
More Related Videos
Related Concept Videos
Endocarditis I: Introduction
Endocarditis III: Medical Management
Endocarditis II: Clinical Features of Infective Endocarditis
Endocarditis IV: Nursing Management
Aortic Regurgitation I: Introduction
Mitral Stenosis III: Medical Management

